跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2021-001637-39-DK
EUCTR2021-001637-39-DK进行中（未招募）1 期

Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 Alone or in Combination with RP-3500 in Patients with Advanced Solid Tumors - MYTHIC study

Repare Therapeutics0 个研究点目标入组 180 人开始时间: 2021年5月5日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
180
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Written informed consent and assent, according to local guidelines, signed and dated by the participating patient or legal guardian prior to the performance of any study-specific procedures, sampling, or analyses.
  • •2. Male or female and =12 years-of-age at the time of signature of the informed consent form (ICF).
  • •3. Lansky performance status =50 for patients =16 years of age, or ECOG score of 0, 1, or 2 (Module 2 ECOG 0 or 1) for patients >16 years of age.
  • •4. All patients must have locally advanced or metastatic resistant or refractory solid tumors. Patients <18 years-of-age will be eligible only if standard or available curative therapy does not exist. Patients =18 years-of-age are eligible if, in the opinion of the investigator, the patient is not a candidate for, or would be unlikely to tolerate or derive significant clinical benefit from, appropriate standard-of-care therapy, or if the patient declines standard-of-care therapy.
  • •5. Patients <18 years of age must weigh at least 40 kg.
  • •6. Archived tumor tissue sample available or lesion that can be safely biopsied if the archival sample is not available.
  • •7. All patient’s tumors, except for types of endometrial cancer listed in criteria #8, must have evidence of at least one of the following as reported by a local CLIA-certified or equivalent (ex-United States [US]) laboratory and centrally confirmed by PODS:
  • •a. CCNE1 amplification (non-equivocal) as determined by either a tumor or plasma NGS test, or FISH
  • •b. FBXW7 deleterious mutations identified by either a tumor or plasma NGS test
  • •c. Proprietary gene deleterious mutations identified by either a tumor or plasma NGS test
  • •d. For backfill cohorts, tumors with other genes with mechanistic rationale agreed upon between the Sponsor and Investigator will be accepted.
  • •8. The following types of endometrial cancer are eligible (for Module 1 only):
  • •a. Serous endometrial cancer (p53 IHC must be confirmed to be aberrant or local NGS report confirming TP53 loss of function mutation must be provided)
  • •b. Carcinosarcoma of the endometrium
  • •c. Grade 3 endometrioid and undifferentiated carcinoma (p53 IHC must be confirmed to be aberrant or local NGS report confirming TP53 loss of function mutation must be provided; MMR IHC must be retained and/or tumor must be MSS; polymerase epsilon (POLE) hypermutated type must be excluded)
  • •9. Measurable disease as per RECIST v1.1.
  • •10. Ability to comply with the protocol and study procedures detailed in the Schedule of Assessments.
  • •11. Ability to swallow and retain oral medications.
  • •12. Acceptable organ function at Screening, as evidenced by the following laboratory data:
  • •a. Serum creatinine =1.5 × ULN or calculated creatinine clearance =60 mL/min using the Cockcroft-Gault equation or by 24-hour urine collection
  • •b. Total bilirubin =1.5 × ULN or <3.0 × ULN if known Gilbert’s disease
  • •c. Serum albumin =2.5 g/dL
  • •d. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =3.0 × ULN
  • •13. Acceptable hematologic function at Screening:
  • •a. No red blood cell (RBC) or platelet transfusions or growth factors within 7 days of the first dose of RP-6306
  • •b. Hemoglobin =9.0 g/dL (or =10.0 g/dL for Module 2 only)
  • •c. ANC =1500 cells/mm3
  • •d. Platelet count =100,000 cells/mm3
  • •14. Negative pregnancy test (serum) for women of childbearing potential at Screening.
  • •15. Male patients with female partners of childbearing potential must follow a contraception method (oral contraceptives allowed) during their participation in the study

排除标准

  • •1. Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 half-lives, whichever is shorter, prior to first dose of study drug. For drugs for which 5 half-lives is =21 days, a minimum of 10 days between termination of the prior treatment and administration of RP-6306 treatment is required. For patients with breast or prostate cancer, continuation of long-term luteinizing hormone-releasing hormone (LHRH), gonadotrophin releasing hormone (GnRH), or previously prescribed Receptor Activator of Nuclear Factor kB Ligand (RANKL) inhibitor are allowed if these medications were prescribed for at least 3 months before trial entry. Bisphosphonates are allowed if prescribed at least 28 days prior to enrollment.
  • •2. History or current condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results, or interfere with the patient’s participation for the full duration of the study treatment.
  • •3. Patients who are pregnant or breastfeeding.
  • •4. Known sensitivity to any of the ingredients of RP-6306 (and RP-3500 for Module 2).
  • •5. Patient who are unable to swallow oral medications.
  • •6. Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction (such as ascites requiring drainage within 4 weeks prior to enrollment, coagulopathy, or encephalopathy), or other reasons which, in the investigator’s opinion, could compromise the participating patient’s safety, or interfere with or
  • •compromise the integrity of the study outcomes.
  • •7. Major surgery (excluding placement of vascular access) within 4 weeks prior to first dose of RP-6306.
  • •8. Uncontrolled, symptomatic brain metastases. Patients with previously treated brain metastases may participate provided the metastases are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of study drug and any neurologic symptoms are controlled and stable), have no evidence of new or enlarged brain metastases, and are clinically stable and off steroids for at least 7 days prior to study drug.
  • •9. Uncontrolled hypertension (systolic blood pressure [BP] =160 mmHg; diastolic BP =100 mmHg) despite adequate treatment prior to first dose of RP-6306 (and RP-3500 for Module 2).
  • •10. Active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness. In equivocal cases, patients whose viral load is negative, may be eligible. HIV seropositive patients who are healthy and low risk for AIDSrelated outcomes could be considered eligible. Eligibility criteria for HIV positive patients should be evaluated and discussed with the sponsor’s medical monitor and will be based on current and past CD4 and T-cell counts, history (if any) of AIDS defining conditions (e.g., opportunistic infections), and status of HIV treatment
  • •11. Moderate or severe hepatic impairment (i.e., Child-Pugh class B or C).
  • •12. Any of the following cardiac diseases currently or within the last 6 months as defined by New York Heart Association (NYHA) =Class 2:
  • •a. Unstable angina pectoris
  • •b. Congestive heart failure
  • •c. Acute myocardial infarction
  • •d. Conduction abnormality not controlled with pacemaker or medication
  • •e. Significant ventricular or supraventricular arrhythmias (patients with chronic rate-controlled atrial fibrillation in the absence

研究者

相似试验

进行中（未招募）
1 期
Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104
CTIS2024-511259-16-00Repare Therapeutics USA Inc.80
进行中（未招募）
1 期
Study of the Safety and Pharmacokinetics of Venetoclax in Children and Young Adults with Relapsed or Refractory Malignancies
EUCTR2017-000439-14-FRAbbVie Deutschland GmbH & Co. KG135
已完成
不适用
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancieson-Hodgkin lymfomen, neuroblastoom en overige solide tumorenAML/ALL/NHL/NeuroblastomaPediatric cancer10024324
NL-OMON50736AbbVie B.V.4
已完成
1 期
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid TumorsAdvanced Cancer
JPRN-jRCT2080223608Bristol-Myers Squibb K.K.21
进行中（未招募）
1 期
Study of the Safety and Pharmacokinetics of Venetoclax in Children and Young Adults with Relapsed or Refractory MalignanciesIn Part 1 patients with any relapsed or refractory tumor will be eligible to enroll. During Part 2 patients with the following malignancies: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), or neuroblastoma are eligle to enroll. In addition patients with any tumor that expresses BCL-2 can also enrol.
EUCTR2017-000439-14-NLAbbVie Deutschland GmbH & Co. KG135